Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients ...
Chef Elle Simone Scott was the first Black woman to join the cast of “America’s Test Kitchen,” redefining representation in ...
ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...
The therapy, A2B543, will be added as an arm to the ongoing Phase I/II EVEREST-2 trial, which is testing CAR T-cell products developed using A2's Tmod platform. According to A2, the Tmod platform ...
Promising ovarian cancer research by Melanie Rutkowski, PhD, at the University of Virginia Comprehensive Cancer Center has ...
Cannabidiol (CBD), a non-intoxicating compound in marijuana, “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties, a new scientific review ...
Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...
University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.
Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...
“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...
Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback